IFP Advisors Inc Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

IFP Advisors Inc boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 44.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 178,547 shares of the biopharmaceutical company’s stock after purchasing an additional 54,983 shares during the period. IFP Advisors Inc’s holdings in TG Therapeutics were worth $5,374,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Creative Planning grew its position in shares of TG Therapeutics by 19.2% during the 3rd quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company’s stock valued at $1,306,000 after purchasing an additional 8,993 shares in the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. Raymond James & Associates grew its position in TG Therapeutics by 35.9% during the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company’s stock worth $3,980,000 after buying an additional 44,972 shares in the last quarter. Private Advisor Group LLC increased its stake in TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of TG Therapeutics in the 3rd quarter valued at about $1,509,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 6.0 %

Shares of TGTX opened at $29.02 on Tuesday. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $36.84. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of -290.17 and a beta of 2.26. The firm has a 50 day moving average price of $30.96 and a 200-day moving average price of $27.90. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TGTX shares. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target for the company. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. increased their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.